Yazar "Yalcin, Selim" seçeneğine göre listele
Listeleniyor 1 - 11 / 11
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Could erythropoietin reduce the ovarian damage of cisplatin in female rats?(Taylor & Francis Ltd, 2018) Sayan, Cemile Dayangan; Tulmac, Ozlem Banu; Karaca, Gokhan; Ozkan, Zehra Sema; Yalcin, Selim; Devrim, Tuba; Badem, Nermin DindarThe aim of this study is to investigate whether erythropoietin (EPO) can reduce the ovarian damage of cisplatin or not. Thirty, female, Wistar-Albino rats were used in the study. Control group (N=10): Intraperitoneal saline infusion, Cisplatin group (N=10): Intraperitoneal 7mg/kg cisplatin, Cisplatin+EPO group (N=10): Intraperitoneal 7mg/kg cisplatin and subcutaneous 200IU/kg/day EPO. Serum AMH concentrations were measured by enzyme-linked immunosorbent assay kit of AMH. Follicular counts were evaluated according to mean diameter of the follicles. Ovarian damage; including follicular cell degeneration, vascular congestion, hemorrhage, and inflammation was scored histologically using a graduated scale. Posttreatment AMH levels of cisplatin group were significantly lower than control and cisplatin+EPO groups. In cisplatin group, there was a significant decrement in posttreatment AMH level compared to pretreatment AMH level. The total damage score of cisplatin group was significantly higher than scores of control and cisplatin+EPO groups. The mean primordial follicle counts of control and cisplatin+EPO groups were significantly higher than that of cisplatin group (p=.007 and p=.003). The results of this study revealed that EPO administration to cisplatin chemotherapy could ameliorate the ovarian damage. Erythropoietin administration to chemotherapeutic agents might suggest to protect ovarian failure and infertility.Öğe Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results(Tubitak Scientific & Technical Research Council Turkey, 2019) Albuzi, Ozgur; Dulger, Dilek; Tunali, Beste Cagdas; Aydin, Feray; Yalcin, Selim; Turk, MustafaBoron oxide (B2O3) is derived from dehydration of boric acid and is a colorless, semitransparent, crystalline compound that is moderately soluble in water. On the other hand, boron oxide is chemically hygroscopic. This gives the molecule the ability to soak up water and adhere to tissues. Boron oxide can be used locally after tumor debulking in inoperable tumors and especially when the twnor-free margin distance cannot be provided. For all these reasons we aimed to evaluate the in vitro test results of B2O3, in terms of cytotoxicity, genotoxicity, apoptosis, and necrotic effects on L929 fibroblast cells and DLD-1 colorectal adenocarcinoma cells. Our studies demonstrated that boron oxide compounds appear to be highly cytotoxic for both cell lines according to WST cell viability assay (44.22% and 18.36% on DLD-1 and L929, respectively). Although no genotoxic effects were observed, boron oxide compounds showed antiproliferative effects for both cell lines. The prepared boron oxide compounds may hold the potential to be applied locally to the remaining tissue after surgery and further research and evaluation will be needed to determine its effectivenesss.Öğe Evaluation of the Brachial Plexus With Shear Wave Elastography After Radiotherapy for Breast Cancer(Wiley, 2018) Kultur, Turgut; Okumus, Muyesser; Inal, Mikail; Yalcin, SelimObjectivesThe aim of this study was to analyze the elasticity characteristics of the brachial plexus by shear wave elastography (SWE) in patients receiving radiation therapy (RT) for breast cancer and to compare them with their contralateral brachial plexus to evaluate whether elasticity properties can be used as supporting findings for the early diagnosis of brachial plexus involvement in patients receiving RT. MethodsA prospective analysis with electromyography and SWE was performed on 23 brachial plexuses of patients receiving RT for breast cancer and their contralateral brachial plexuses. An electromyographic device was used for nerve conduction studies. Evaluations were done by the same investigator, and superficial electrodes were used in the recordings. A quantitative analysis of the brachial plexus with SWE was performed, with values in kilopascals on a color scale ranging from 0 (red, soft) to 150 (dark blue, hard) kPa. ResultsMean SWE valuesSD were 51.0 +/- 14.0 kPa for the ipsilateral brachial plexuses of patients receiving RT and 18.0 +/- 4.2 kPa for the contralateral brachial plexuses. Statistically significant differences were observed between the groups in the analysis of SWE values (P<.001). No significant correlation was found between the nerve conduction parameters and elastographic values (P>.05). ConclusionsShear wave elastography showed that the brachial plexuses of patients receiving RT were stiffer than the unaffected brachial plexuses. Brachial plexus stiffening may be associated with fibrotic processes.Öğe Idiopathic Hypereosinophilic Syndrome as a Rare Cause of Stroke: A Case Report(Turkish Neurological Soc, 2021) Turgut, Esra; Alpua, Murat; Yalcin, Selim; Coskun, Oya; Bilgili, Mirace Yasemin Karadeniz; Acikgoz, Ergin Ayaslioglu; Coskun, OzlemHypereosinophilic syndrome (HES) is a rare hematological disease that causes organ damage by eosinophil infiltration in the tissue with increased eosinophil production in the bone marrow. HES is a rare but important cause of stroke. Central nervous system involvement findings can be serious and life-threatening. Eosinophil values should be examined as the cause of stroke, and hypereosinophilia should be suspected, especially in young patients with no etiology. Reported herein is a case of a 47-year-old female patient who was followed up with the diagnosis of acute cerebrovascular disease due to idiopathic HES.Öğe Is C-Reactive Protein/Albumin Ratio of Advanced-Stage Non-small Cell Lung Cancer Patients Able to Predict Mortality in the Admission for Palliative Care?(WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020) Karahan, Irfan; Yalcin, SelimContext: Lung cancer is frequent and mortal cancer. The predicting mortality may be helpful for cancer management. Aim: The purpose of the study was to evaluate the role of baseline C-reactive protein (CRP)/albumin ratio (CAR) in relation to hospital mortality, the setting of advanced stage non-small cell lung cancer (NSCLC). Materials and Methods: The present study is a retrospective analysis and included 77 adult patients with Stage IV NSCLC who were hospitalized for supportive care. All patients are divided into two groups as survivors and nonsurvivors. CAR on the admission was compared between groups. The correlation between CAR and the death time was investigated. The cutoff level of CAR was calculated, and patients with a high level were described in two groups. Results: For all participants, the mean age was 63.0 +/- 9.9 years, and the median values of CRP and albumin levels were 15.3 mg/dl (1-51.5) and 5.7 g/dl (0.02-22.7), respectively. CAR was significantly lower in the survivor group. By receiver operation curve analysis, the cutoff levels of CRP and CAR were determined as 10.8 and 3.5, respectively. The odds ratio of mortality was 3.85 (1.49-9.94 95% confidence interval [CI], P = 0.006) for higher than cutoff levels of CAR. The odds ratio was 3.38 (1.32-8.65 95% CI, P = 0.01) for higher CRP levels. There was a significant but weak negative correlation between the time of death and both CRP and CAR in the nonsurvivor group (r = -0.46, P = 0.002; r = -0.48, P = 0.001, respectively). Conclusion: The present study showed that CAR was significantly increased in nonsurvivors. CAR may be a cheap, easy, and effective tool for predicting the death and its time of hospitalized NSCLC patients.Öğe Nivolumab-induced sensory ganglionopathy(Sage Publications Ltd, 2023) Coskun, Ozlem; Sahin, Hasan; Yalcin, Selim; Sahin, Yekta C.; Coskun, UgurIntroduction Nivolumab is s a human monoclonal antibody. Due to its widespread use in many cancers, including Merkel cell carcinoma, adverse reactions associated with nivolumab, such as neuropathies, endocrinopathies, gastrointestinal problems, and skin toxicities have been increasing. Sensory ganlionopathy is rarely observed in these patients. Case description We present a 63-year-old male with a medical history of Merkel cell carcinoma that recurred two times in the inguinal region. After undergoing surgery with adjuvant radiotherapy, a second surgery was performed. The patient suffered from tingling in all four limbs plus difficulty in walking after initiation of the third dose of nivolumab. Management and outcome After 1 month of 1 mg/kg/day methylprednisolone treatment, he showed significant improvement. Subsequently, the systemic corticosteroid regimen was tapered to 5 mg every other day. The treatment resulted in significant improvement in all extremities. Discussion Sensory ganlionopathy can be seen as a side effect of an immune checkpoint inhibitor, even though it is very extraordinary. This is the case in the literature to develop sensory ganlionopathy due to nivolumab. We believe that patients using nivolumab may develop sensory ganlionopathy and management should be taken on this point.Öğe Prognostic effects of SuPAR and Neopterin Levels on Patients with Lung Cancer(WALTER DE GRUYTER GMBH, 2020) Yalcin, Selim; Demir, Mehmet Emin; Ozturk, Reyhan; Kilinc, Aytun Sadan; Suer, Hatice; Karahan, IrfanBackground: Two unique biomarkers, soluble form of the urokinase-type plasminogen activator receptor (suPAR) and neopterin, play a crucial role in inflammatory processes. This study aimed to reveal whether it is possible to utilize these biomarkers in predicting tumor prognosis in patients with lung cancers. Methods: The present study was designed as a single center, prospective, and controlled research. The study was conducted with forty patients with lung cancer (case group) and 41 healthy individuals (control group) in Kirikkale University, Faculty of Medicine between 2016-2020. The case group was also divided into two of the early and advanced stages. The blood samples were drawn to evaluate suPAR and neopterin levels, and these parameters were compared between the case and control groups. Also, the prognostic effects of age, stage of the tumor, and the levels of mentioned parameters were investigated with the survival analysis. Results: The median duration of the follow-up was 32 (4-75) months. suPAR and neopterin levels were found to be higher in the case group than in the control group. Cox regression showed that the high levels of neopterin and suPAR increased mortality risk [1)=0.002, HR: 1.25 (1.081.45 95%CI) and p=0.023, HR:1.07 (1.01-1.13), respectively]. Finally, age and stage of the tumor were found to have no relationship with survival. Conclusion: suPAR and neopterin as members of the inflammatory pathway were found to be higher in cancer cases. Furthermore, both suPAR and neopterin levels were found to be predictive for the mortality of patients with lung cancers; therefore, they are thought to be used for the management of cancer.Öğe Signet-ring cells in the skin: a case of late-onset cutaneous metastasis of gastric carcinoma and a brief review of histological approach(Pagepress Publ, 2016) Gunduz, Ozgur; Emeksiz, Mehmet Can; Atasoy, Pinar; Kidir, Mehtap; Yalcin, Selim; Demirkan, SerkanUp to 10% of patients with visceral malignancies develop skin metastases during their clinical course and these metastases constitute about 2% of all skin cancers. Skin metastasis may be the first sign of a clinically silent visceral cancer or represent recurrence of an internal malignancy. In both situations, they are associated with poor prognosis, which can partly be attributed to underdiagnosis. In this paper, a case of relapsing gastric adenocarcinoma, which manifested itself as asymptomatic cutaneous papules and nodules on a patient's head and neck, is reported and histopathological approach to the cutaneous lesions containing signet-ring cell is briefly reviewed.Öğe The effects of trastuzumab therapy on endothelial functions of breast cancer patients(Assoc Medica Brasileira, 2024) Alp, Caglar; Dogru, Mehmet Tolga; Yalcin, Selim; Karal, Ali OguzhanOBJECTIVE: Breast cancer is among the highest causes of morbidity and mortality in women. Trastuzumab therapy, which is known to be significantly cardiotoxic, is mainly used to treat patients with resistant breast cancer, including estrogen receptor-positive type. We aimed to show the effects of METHODS: In this study, a total of 26 participants (24 female and 2 male patients, minimum age: 38 years, maximum age: 79 years, and mean age 57.3 +/- 12.7 years) were enrolled in the study. For the statistical evaluation of data, we classified the participants of the study as follows: Pretreatment: Before trastuzumab therapy; Treatment Period 1: 1 month after the first dose of trastuzumab; Treatment Period 2: 4 months after the first dose of trastuzumab; Treatment Period 3: 12 months after the first dose of trastuzumab. We conducted repeated-measures analysis of variance (Greenhouse-Geisser) and paired-sample t-tests to statistically compare the groups using flow-mediated dilation measurements. RESULTS: We determined that there are statistically significant differences between flow-mediated hyperemia and ratio values (flow-mediated dilation) of the groups (p<0.009 and p<0.001, respectively). CONCLUSION: Our data indicate that trastuzumab therapy could have negative effects on endothelial functions in breast cancer patients.Öğe The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study(Springer Japan Kk, 2024) Yildirim, Hasan Cagri; Kutlu, Yasin; Mutlu, Emel; Aykan, Musa Baris; Korkmaz, Mustafa; Yalcin, Selim; Sakalar, TeomanIntroductionMale breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 -) breast cancer in women, limited data exist on their effectiveness in male patients.We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer.IntroductionMale breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 -) breast cancer in women, limited data exist on their effectiveness in male patients.We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer.MethodsThis study is a multicenter, retrospective study. We included male patients with HR + and HER2-metastatic breast cancer who received palbociclib or ribociclib as first-line treatment. Our primary endpoints were progression-free survival (PFS), overall response rates (ORR), and drug-related adverse effects.ResultsA total of 46 male patients from 27 institutions were enrolled. The median age at initiation of CDK 4/6 inhibitors was 63.64 +/- 13.69 years, with a median follow-up of 21.33 (95% CI 14.92-27.74) months. The ORR were 84% for palbociclib and 76.2% for ribociclib. The mPFS for the entire cohort was 28.06 months (95% CI 18.70-37.42). No significant difference in PFS was observed between palbociclib and ribociclib (mPFS: 24.46 months (95% CI 11.51-37.42) vs 28.33 months (95% CI 14.77-41.88), respectively, p = 0.211). No new adverse events were reported.DiscussionThis study demonstrates that palbociclib and ribociclib are effective and safe options for first-line treatment in male patients with HR + /HER2 - metastatic breast cancer. However, further prospective studies are warranted to establish their efficacy in this population.Öğe The prediction of lung cancer prognosis with blood lipid levels and ratios at the time of diagnosis(Wolters Kluwer Medknow Publications, 2022) Arslan, Ferhat; Yalcin, Selim; Karahan, IrfanBackground: Emerging evidence has linked lipid metabolism disorder with lung diseases, but the relationship between blood lipid profile and lung cancer risk is controversial and inconclusive. It was aimed to investigate the relationship of lipid levels and ratios at the time of diagnosis to the prognosis prediction of lung cancer. Methods: Sociodemographic and disease-related clinical characteristics of 92 patients diagnosed with lung cancer were reviewed retrospectively. Patients with available lipid parameters at the time of diagnosis were evaluated. Hemogram parameters of the patients included in the study, creatinine and estimated glomerular filtration rate, alanine aminotransferase level, albumin level, C-reactive protein level, as well as total cholesterol (TC)/high-density cholesterol (HDL) ratio, non-HDL/HDL ratio, low-density lipoprotein/HDL ratio, and triglyceride/HDL ratios were examined. Results: The mean age at presentation was 64.2 +/- 9.1 years. The distribution of lung cancers is 6 (6.5%) for small cell lung cancer (SCLC) and 86 (93.5%) for non-SCLC. The median follow-up period of the patients is 12 months. During the follow-up, 63 (68.5%) of the patients died. In the univariate analysis, increased non-HDL/HDL ratio was related to mortality. In multivariate analysis, disease stage, albumin level, and TC level were found to be variables affecting the mortality. Conclusion: TC levels at the time of diagnosis can be a guide in determining the prognosis. More experimental studies are needed to elucidate the relationship between the lipid metabolism and lung cancer etiology and to determine the role of lipid levels and ratios in prognosis prediction.
